Aurorean to Deliver Secure, Internet-Based Connectivity to Gambro Renal Products’
Worldwide Dialysis Clinics
NEWBURY, ENGLAND & LUND, SWEEDEN – January 17, 2002 – Enterasys Networks Inc. (NYSE: ETS), a leader in enterprise networking solutions, has announced that Gambro Renal Products, part of Gambro AB, has selected Enterasys’ Aurorean Virtual Private Network (VPN) technology. The leading provider of kidney dialysis services is utilising Enterasys’ advanced VPN solution to build a global virtual network between its central site in Lund, Southern Sweden, its branch offices, and its worldwide network of dialysis clinics.
Gambro Renal Products’ investment in Enterasys’ Aurorean Virtual Network (AVN) will provide secure, Internet-based connectivity between 100 global sites, 58 percent of which are based in the United States. The Aurorean solution will leverage inherent security with the cost-effective nature of the public Internet, allowing Gambro Renal Products to streamline staff communication, ensure the confidentiality of patient information and medical records, and achieve cost-predictability for its new WAN infrastructure.
The VPN solution will also extend Gambro Renal Products’ central network and resources to field employees, allowing mobile staff to conduct business quickly and securely from remote locations such as hotel rooms. The project was won in association with Enterasys’ partner Lindahl & Rothoff, and was completed in October 2001.
“We have an extensive global intranet that is the foundation of our internal business communications functions. With such a distributed organisation it’s imperative that we implement a flexible and scalable network infrastructure,” commented Gambro Renal Products’ Systems Manager, Bengt-Åke Friis. “Aurorean meets our technical requirements exactly. The system is valuable and is simple to configure and monitor.”
The Enterasys ANG-7050 is installed within Gambro’s central site in Lund. A high-performance network gateway, the ANG-7050 supports up to 5,000 concurrent VPN connections and delivers high levels of security. Alongside the ANG-7050, Enterasys’ APS-7000 policy server delivers complete control of the global virtual network, including centralised authentication, policy-based access control, configuration and fault management. The ANG portfolio of products, a cornerstone of Enterasys’ Secure Harbour architecture, the industry’s first holistic architecture for secure network infrastructure, conforms to the IPsec and IKE security protocols and provides dynamic IP address allocation, SNMP monitoring, and secure web-based management.
Dialysis clinics and remote offices have been installed with ANG-1102 remote VPN access devices. These low-cost, next-generation SOHO VPN gateways support secure information tunnels back to the central site and feature integrated firewall technology to protect these always-on Internet connections.
Mobile workers utilise the Aurorean Client Software, an intelligent, full-featured application that provides a simple, efficient, and cost-effective connection to corporate servers. Enterasys’ new NetSight Gateway Monitoring Tool (GMT) provides in-depth, secure, centralised web-based management of the VPN solution.
“VPNs continue to offer the geographical reach and cost-effectiveness of the Internet. Combining both with high levels of security ensures that organisations gain the confidence to transmit confidential information over a public network. Gambro Renal Products’ investment in Enterasys’ Aurorean VPN technology is delivering connectivity to 100 remote offices and will allow for simple expansion to additional locations should the need arise. With this ability, VPN technology should be viewed as an attractive financial and technical proposition, with the added capability of delivering predictive WAN cost models,” said Gerard Vivier, president of Enterasys Networks - Europe, Middle East & Africa (EMEA).
For more information on Enterasys’ complete portfolio of Aurorean VPN solutions, please visit http://www.enterasys.com/aurorean
Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Renal Products is one of the leading providers of kidney dialysis services in the world with about 50,000 patients in 670 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenues of approximately SEK 22 billion (USD 2.4 billion), has approximately 19,500 employees in some 40 countries.
For more information please visit http://www.gambro.com
About Enterasys Networks
Enterasys Networks (NYSE: ETS) is a leading worldwide provider of communications infrastructures for enterprise-class customers. Enterasys’ networking hardware and software offerings deliver the innovative security, availability and mobility solutions required by Global 2000 organizations coupled with the industry’s strongest service and support.
For more information, visit http://www.enterasys.com
Tel: +44 1635 810723
Martin Brindley/Adrian Brophy
MCC International Ltd
Tel: +44 1962 888100
This press release was distributed by ResponseSource Press Release Wire on behalf of MCC International Ltd in the following categories: Consumer Technology, Personal Finance, Business & Finance, Computing & Telecoms, for more information visit https://pressreleasewire.responsesource.com/about.